Two Sigma Advisers LP Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX)

Two Sigma Advisers LP reduced its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 53.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,400 shares of the company’s stock after selling 19,800 shares during the period. Two Sigma Advisers LP’s holdings in Annexon were worth $89,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new position in Annexon in the 4th quarter worth $59,000. CANADA LIFE ASSURANCE Co purchased a new position in shares of Annexon in the fourth quarter worth about $77,000. E Fund Management Co. Ltd. raised its stake in shares of Annexon by 36.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after purchasing an additional 4,086 shares during the last quarter. Forefront Analytics LLC lifted its holdings in shares of Annexon by 56.8% during the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock worth $84,000 after purchasing an additional 5,950 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new stake in Annexon in the fourth quarter valued at approximately $98,000.

Annexon Stock Performance

Shares of ANNX stock opened at $2.60 on Monday. Annexon, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $7.85. The stock’s fifty day moving average is $1.84 and its two-hundred day moving average is $3.17. The firm has a market capitalization of $285.26 million, a P/E ratio of -2.48 and a beta of 1.26.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.07). On average, equities analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current year.

Analyst Ratings Changes

ANNX has been the subject of several recent research reports. HC Wainwright reduced their target price on shares of Annexon from $20.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Needham & Company LLC reduced their price objective on Annexon from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.